Vivian Choi is the Vice President of Liver Programs and Nonclinical Development at Prime Medicine and she previously led the Liver, Lung, Metabolic, Eye and Ear group at Prime, overseeing multiple portfolio programs and functions. Before joining the biotech industry, she built and led gene therapy research organizations at Novartis, Shire and Takeda with increasing responsibilities and providing scientific and strategic leadership to advance programs from discovery through clinical translation. Her experience spans viral and non-viral delivery, gene transfer, gene regulation, and genome editing across ophthalmic, neuromuscular, lysosomal storage, and rare liver diseases. Her academic training focused on AAV biology and delivery, in vivo gene therapy, and DNA recombination and repair. She earned a B.S. in Biochemistry from the University of Wisconsin-Madison, a Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill and completed postdoctoral training at Harvard Medical School. Her career has focused on translating emerging genetic technologies into medicines.